CF101 (Dry Eye Syndrome)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.1.3 Classification 15
3.1.4 Prognosis 15
3.1.5 Quality of Life 16
3.2 Symptoms 16
4 Disease Management 18
4.1 Overview 18
4.1.1 Diagnosis Overview 18
4.1.2 Treatment Guidelines 21
4.1.3 Treatment Overview 25
5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 28
6 Opportunity and Unmet Need 30
6.1 Overview 30
6.2 Diagnostic tests are not specific enough to identify subgroups of patients 31
6.3 Frequent dosing and side effects limit compliance 32
6.4 Lack of physician and patient awareness 33
6.5 Trial design may be a factor in so few drugs being approved 34
6.6 Unmet Needs Gap Analysis 35
6.7 Comprehensive method for measuring dry eye signs and severity levels 36
6.8 Increase treatment rates among milder forms of the disease 37
7 Pipeline Assessment 38
7.1 Overview 38
7.2 Promising drugs in clinical development 39
8 CF-101 41
8.1 Overview 41
8.2 Efficacy 42
8.3 Safety 42
8.4 Dosing and Formulation 42
8.5 Potential Clinical Positioning 43
8.6 Potential Commercial Positioning 43
8.7 Pricing and Reimbursement 43
8.8 SWOT Analysis 44
8.9 Forecast 44
9 Appendix 46
9.1 Bibliography 46
9.2 Abbreviations 48
9.3 Methodology 50
9.4 Forecasting Methodology 50
9.4.1 Diagnosed DES patients 50
9.4.2 Percent Drug-treated Patients 51
9.4.3 General Pricing Assumptions 51
9.4.4 Individual Drug Assumptions 52
9.4.5 Generic Erosion 52
9.5 Physicians and Specialists Included in this Study 52
9.6 About the Authors 53
9.6.1 Author 53
9.6.2 Global Head of Healthcare 54
9.7 About GlobalData 54
9.8 Contact Us 54
9.9 Disclaimer 55